The RalGAP1 Complex: A Protein-Protein Interaction PPI Regulating Cell Signaling Pathways

Target Name: RalGAP1 complex

NCBI ID: P16383

RalGAP1 complex

Other Name(s): None

The RalGAP1 Complex: A Protein-Protein Interaction PPI Regulating Cell Signaling Pathways

The RalGAP1 complex is a protein that plays a critical role in regulating cell signaling pathways, and it is a potential drug target or biomarker in various diseases. The RalGAP1 complex is composed of four subunits: RalGAP1, RalGAP2, RalGAP3, and RalGAP4.

RalGAP1 is the key subunit of the RalGAP1 complex and is responsible for the N-terminal region of the protein. It has a catalytic active site and is involved in the regulation of several cellular processes, including cell signaling pathways, cell adhesion, and cell cycle progression.

The RalGAP1 complex functions as a protein-protein interaction (PPI) complex, meaning that it consists of two or more protein subunits that interact with each other to regulate protein function. The RalGAP1 complex is composed of four subunits that are involved in different aspects of protein function, including N-terminal signaling, S-terminal signaling, T-terminal signaling, and N-terminal-S-terminal signaling.

The N-terminal signaling subunit of the RalGAP1 complex is RalGAP1 itself. RalGAP1 functions as a kinase, catalyzing the formation of a covalent complex with its protein partner, also known as a cofactor or substrate. This reaction is known as nucleotide exchange and is a critical step in the regulation of cellular processes, including cell signaling pathways.

The S-terminal signaling subunit of the RalGAP1 complex is RalGAP2. RalGAP2 is a protein that contains a nucleotide-binding oligomerization (NBO) domain, which is involved in the regulation of protein-protein interactions and is a potential drug target in various diseases.

The T-terminal signaling subunit of the RalGAP1 complex is RalGAP3. RalGAP3 is a protein that contains a nucleotide-binding oligomerization (NBO) domain and is involved in the regulation of protein-protein interactions and cell signaling pathways.

The N-terminal-S-terminal signaling subunit of the RalGAP1 complex is RalGAP4. RalGAP4 is a protein that contains a nucleotide-binding oligomerization (NBO) domain and is involved in the regulation of protein-protein interactions and cell signaling pathways.

The RalGAP1 complex plays a critical role in the regulation of cellular processes, including cell signaling pathways, cell adhesion, and cell cycle progression. It is a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The RalGAP1 complex is a protein-protein interaction (PPI) complex that consists of four subunits: RalGAP1, RalGAP2, RalGAP3, and RalGAP4. RalGAP1 is the key subunit of the complex and is involved in the N-terminal signaling subunit of the complex. RalGAP2, RalGAP3, and RalGAP4 are involved in the S-terminal, T-terminal, and N-terminal-S-terminal signaling subunits of the complex, respectively.

The RalGAP1 complex is a protein that plays a critical role in regulating cell signaling pathways, and it is a potential drug target or biomarker in various diseases. The RalGAP1 complex is composed of four subunits: RalGAP1, RalGAP2, RalGAP3, and RalGAP4, and functions as a protein-protein interaction (PPI) complex that is involved in the regulation of several cellular processes, including cell signaling pathways, cell adhesion, and cell cycle progression.

Protein Name: RalGAP1 Complex

The "RalGAP1 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RalGAP1 complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets